Compare Hershey Co (HSY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hershey Co vs Vertex Pharmaceuticals Incorporated — how do they compare? Hershey Co trades at $162.6 (market cap $32.66B), while Vertex Pharmaceuticals Incorporated trades at $514.06 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 3.9× Hershey Co's market cap, and Hershey Co pays a 3.57% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hershey Co for 135 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| HSY | VRTX | |
|---|---|---|
Market Cap | $32.66B | $127.55B |
Volume | 1,578,237 | 1,487,944 |
Sector | Consumer Staples | Health |
52-Week High | $236.28 | $557.96 |
52-Week Low | $157.61 | $407.37 |
Typical Hold Time | 135 Days | 120 Days |
Enterprise Value | $37.79B | $121.68B |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hershey (HSY) trades at $160.34, down 0.29% on the day, with the stock showing bearish technical signals despite strong recent earnings beats. The company maintains solid profitability with a 12.24% net margin and 32.81% ROE, though 2025 net income declined to $883 million from prior years. Analyst consensus remains cautious with 65.72% hold ratings, but the $204.62 price target suggests 27.6% upside potential. Recent corporate developments include international leadership changes and ongoing brand investments to drive demand.
HSY presents a mixed investment case with attractive valuation upside but near-term headwinds. The stock's current price near support levels offers entry opportunity for dividend investors, with the recent dividend resumption signaling management confidence. However, commodity cost pressures and competitive threats in the consumer staples space create execution risks. Institutional ownership trends show mixed signals with both new positions and reductions in Q2 2026.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
